ADEL
Latest round
- Series B
Last raised
- Aug 2024
Total raised
- $23M
Investors
- 6
About ADEL
Based in South Korea, ADEL, Inc.Founded in 2016, ADEL, Inc. operates from its headquarters in Seoul, South Korea. The company focuses on the development of therapeutic antibodies targeting neurodegenerative diseases.ADEL, Inc. specializes in the development of innovative therapeutic antibodies aimed at treating neurodegenerative diseases, particularly Alzheimer's disease. The company's core product offerings include monoclonal antibodies like Tau-acK280, ß2-microglobulin, and ApoE4, which target protein aggregates linked to Alzheimer's pathology.ADEL, Inc. generates revenue through direct product sales and collaborations with research institutions and pharmaceutical companies. The business model is based on B2B transactions, licensing proprietary technologies and therapeutic products for clinical trials and drug development.In April 2026, ADEL, Inc. The company plans to expand into new markets, particularly targeting North America and Europe, by 2027.
Who invested in ADEL
6 investors across 3 rounds
See all investors in ADEL
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ADEL
Who invested in ADEL?
ADEL has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ADEL raised?
ADEL has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ADEL last raise money?
ADEL's most recent round on record is a Series B, in Aug 2024.
What does ADEL do?
Based in South Korea, ADEL, Inc.
Where is ADEL headquartered?
ADEL is headquartered in Seoul, South Korea.
Which VCs invest in companies like ADEL?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at ADEL's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like ADEL? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.